The consistent elevation of IL-6 in severe COVID-19 made it an attractive target for intervention, especially given the success of anti-IL-6 agents in other cytokine release syndrome conditions such as in reactions to chimeric antigen receptor (CAR)-T-cell therapy. The gene discussed is IL6; the disease is COVID-19.